

## Claims

What is claimed is:

1. A suspension of micronized fenofibrate in a solution of at least one hydrophilic polymer, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/10 and 4/1.
- 5 2. The suspension according to claim 1, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/2 and 2/1.
3. The suspension according to claim 1, wherein the fenofibrate has a size less than 20  $\mu\text{m}$ .
4. The suspension according to claim 1, wherein the fenofibrate is present in an 10 amount from 1 to 40% by weight.
5. The suspension according to claim 4, wherein the fenofibrate is present in an amount from 10 to 25% by weight.
6. The suspension according to claim 1, wherein the hydrophilic polymer is present in an amount from 5 to 40% by weight.
- 15 7. The suspension according to claim 6, wherein the hydrophilic polymer is present in an amount from 10 to 25% by weight.
8. The suspension according to claim 1, wherein the hydrophilic polymer is a polyvinylpyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a hydroxy-methylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.
- 20 9. The suspension according to claim 8, wherein the hydrophilic polymer is a polyvinylpyrrolidone.
10. The suspension according to claim 1, further comprising at least one surfactant.
11. The suspension according to claim 10, wherein the surfactant is present in an amount up to 10% by weight.
- 25 12. The suspension according to claim 11, wherein the surfactant is present in an amount up to 5% by weight.
13. The suspension according to claim 10, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/500 and 1/10.
14. The suspension according to claim 13, wherein the weight ratio of 30 surfactant/hydrophilic polymer is between 1/100 and 5/100.

15. The suspension according to claim 10, wherein the surfactant is sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate, lecithin, stearlyc alcohol, cetostearlyc alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, 5 poloxamer, or a mixture of two or more thereof.
16. The suspension according to claim 15, wherein the surfactant is sodium lauryl sulfate.
17. The suspension according to claim 10, wherein the fenofibrate and surfactant are co-micronized.
- 10 18. The suspension according to claim 1, wherein the hydrophilic polymer and surfactant are dissolved in the solution.
19. A suspension of micronized fenofibrate in a solution of at least one hydrophilic polymer, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/2 and 2/1, said hydrophilic polymer being polyvinylpyrrolidone.
- 15 20. The suspension according to claim 19, further comprising at least one surfactant.
21. The suspension according to claim 20, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/500 and 1/10.
22. The suspension according to claim 20, wherein the surfactant is sodium lauryl sulfate.
- 20 23. The suspension according to claim 19, wherein the hydrophilic polymer and surfactant are dissolved in the solution.
24. A suspension of micronized fenofibrate in a solution of at least one hydrophilic polymer and at least one surfactant.
- 25 25. The suspension according to claim 24, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/500 and 1/10.
26. The suspension according to claim 25, wherein the weight ratio of surfactant/hydrophilic polymer is between 1/100 and 5/100.
27. The suspension according to claim 24, wherein the surfactant is present in an amount up to 10% by weight.
- 30 28. The suspension according to claim 27, wherein the surfactant is present in an amount up to 5% by weight.

29. The suspension according to claim 24, wherein the surfactant is sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate, lecithin, stearlylic alcohol, cetostearyllic alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, 5 poloxamer, or a mixture of two or more thereof.
30. The suspension according to claim 29, wherein the surfactant is sodium lauryl sulfate.
31. The suspension according to claim 24, wherein the fenofibrate and surfactant are co-micronized.
- 10 32. The suspension according to claim 24, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/10 and 4/1.
33. The suspension according to claim 32, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/2 and 2/1.
- 15 34. The suspension according to claim 24, wherein the fenofibrate has a size less than 20  $\mu\text{m}$ .
35. The suspension according to claim 24, wherein the fenofibrate is present in an amount from 1 to 40% by weight.
36. The suspension according to claim 35, wherein the fenofibrate is present in an amount from 10 to 25% by weight.
- 20 37. The suspension according to claim 24, wherein the hydrophilic polymer is present in an amount from 5 to 40% by weight.
38. The suspension according to claim 37, wherein the hydrophilic polymer is present in an amount from 10 to 25% by weight.
- 25 39. The suspension according to claim 24, wherein the hydrophilic polymer is a polyvinylpyrrolidone, a poly(vinyl alcohol), a hydroxypropylcellulose, a hydroxy-methylcellulose, a hydroxypropylmethylcellulose, a gelatin, or a mixture of two or more thereof.
40. The suspension according to claim 39, wherein the hydrophilic polymer is a polyvinylpyrrolidone.
- 30 41. The suspension according to claim 24, wherein the hydrophilic polymer and surfactant are dissolved in the solution.

42. A suspension of micronized fenofibrate in a solution of at least one hydrophilic polymer and at least one surfactant, said hydrophilic polymer being polyvinylpyrrolidone and said surfactant being sodium lauryl sulfate, and the weight ratio of surfactant/hydrophilic polymer being between 1/500 and 1/10.

5 43. The suspension according to claim 42, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/10 and 4/1.

44. The suspension according to claim 43, wherein the weight ratio of fenofibrate/hydrophilic polymer is between 1/2 and 2/1.

45. The suspension according to claim 42, wherein the fenofibrate has a size less than  
10 20 µm.

46. The suspension according to claim 42, wherein the hydrophilic polymer and surfactant are dissolved in the solution.

47. A suspension of micronized fenofibrate in a solution of polyvinylpyrrolidone and of sodium lauryl sulfate, wherein the weight ratio of fenofibrate/polyvinylpyrrolidone is between  
15 1/2 and 2/1 and the weight ratio of sodium lauryl sulfate/polyvinylpyrrolidone being between 1/500 and 1/10.

48. The suspension according to claim 47, wherein the fenofibrate has a size less than 20 µm.

49. The suspension according to claim 47, wherein the fenofibrate is present in an  
20 amount from 1 to 40% by weight.

50. The suspension according to claim 49, wherein the fenofibrate is present in an amount from 10 to 25% by weight.

51. The suspension according to claim 47, wherein the hydrophilic polymer is present in an amount from 5 to 40% by weight.

25 52. The suspension according to claim 51, wherein the hydrophilic polymer is present in an amount from 10 to 25% by weight.

53. The suspension according to claim 47, wherein the surfactant is present in an amount up to 10% by weight.

30 54. The suspension according to claim 53, wherein the surfactant is present in an amount up to 5% by weight.

55. The suspension according to claim 47, wherein the fenofibrate and surfactant are co-micronized.

56. The suspension according to claim 47, wherein the hydrophilic polymer and surfactant are dissolved in the solution.

5 57. The suspension according to claim 1, wherein the fenofibrate has a size less than 10 µm.

58. The suspension according to claim 19, wherein the fenofibrate has a size less than 10 µm.

10 59. The suspension according to claim 24, wherein the fenofibrate has a size less than 10 µm.

60. The suspension according to claim 42, wherein the fenofibrate has a size less than 10 µm.

61. The suspension according to claim 47, wherein the fenofibrate has a size less than 10 µm.

15